Article
Intravesical agent shows some promise in treating IC
Whistler, British Columbia, Canada-Intravesical hyaluronic acid (Cystistat) appears to be a simple, quick therapy for reducing pain, frequency, and nocturia in patients with interstitial cystitis, according to Austrian and Canadian researchers. The agent may also improve radiation-induced cystitis and reduce bacterial cystitis recurrences in patients with recurrent urinary tract infections, said Marc Riviere, MD, senior vice president at Belleville, Ontario-based Bioniche Life Sciences Inc., who presented a series of pilot studies at the Canadian Urological Association annual meeting.
Related Videos
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
BRCA Mutations in mHSPC: Impact on Therapy Selection
Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
Defining and Managing BCG-Unresponsive NMIBC
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Yahir A. Santiago-Lastra, MD, discusses barriers to vaginal estrogen access
Related Content
